IP Library Granted Patent US 9,155,739
Granted Patent B2
US 9,155,739 · App. 14/666,169 · Granted Oct 13, 2015

Histone deacetylases (HDACs) inhibitors

Inventors: Ji-Wang Chern (Taipei, TW); Chao-Wu Yu (Taipei, TW); Pei-Teh Chang (Taipei, TW)
Assignee: ANNJI PHARMACEUTICAL CO., LTD.
A61K31/517C07D239/91C07D403/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,155,739
App. No.
14/666,169
Granted
Oct 13, 2015
Kind
B2
Abstract

Histone deacetylases inhibitors (HDACIs) and methods for treating cancer in a subject in need thereof are disclosed. The HDACIs comprise a compound of Formula X. or a pharmaceutically acceptable salt thereof. In one embodiment of the invention, R 1 is ethyl; R 2 is 2-phenylethyl; R 3 is hydrogen; R 4 is fluoro; R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and R 6 is hydrogen, or a salt thereof. In another embodiment of the invention, R 1 is ethyl; R 2 is 2-phenylethyl; R 3 is hydrogen; R 4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; R 5 is chloro or fluoro; and R 6 is hydrogen.

Claims (200)

1. A method for inducing cytotoxicities in cancer cells associated with deregulation of the activity of histone deacetylases in a subject in need thereof, comprising:

administering to the subject in need thereof a compound of Formula X:

or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to induce cytotoxicities in the cancer cells associated with deregulation of the activity of histone deacetylases,

(I) wherein:

R 1 is hydrogen, (C 1 -C 6 )alkyl, or (C 3 -C 6 )cycloalkyl;

R 2 is (C 6 -C 18 )aryl, (C 6 -C 18 )aryl(C 1 -C 6 )alkyl, (C 3 -C 18 )heteroaryl(C 1 -C 6 )alkyl, halo(C 6 -C 18 )aryl(C 1 -C 6 )alkyl, or (C 1 -C 6 )alkoxy(C 6 -C 18 )aryl(C 1 -C 6 )alkyl;

R 3 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl;

R 4 is hydrogen, halogen, N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene;

R 5 is hydrogen, halogen, N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene, or amino(C 6 -C 18 )aryl-oxo(C 2 -C 6 )alkenyl; and

R 6 is hydrogen, N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyamino(C 6 -C 18 )aryl (C 1 -C 6 )alkylene, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene;

(II) or wherein:

R 1 , R 2 , R 5 and R 6 are each as defined in (I) above;

R 3 is hydrogen or N-hydroxyamino-oxo(C 2 -C 6 )alkenyl; and

R 4 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene;

(III) or wherein:

R 1 , R 2 , R 4 and R 6 are each as defined in (I) above;

R 3 is as defined in (II) above; and

R 5 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene, or amino(C 6 -C 18 )aryl-oxo(C 2 -C 6 )alkenyl;

(IV) or wherein:

R 1 , R 2 , R 4 , R 5 are each as defined in (I) above;

R 3 is as defined in (II) above; and

R 6 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyamino(C 6 -C 18 )aryl (C 1 -C 6 )alkylene, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene.

2. The method of claim 1 ,

(A) wherein:

R 1 is hydrogen, methyl, ethyl, cyclopropyl, or isopropyl;

R 2 is phenyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-(1H-indol-3-yl)ethyl, 2-(4-fluorophenyl)ethyl, or 2-(4-methoxyphenyl)ethyl;

R 3 is (2E)-3-N-hydroxyamino-3-oxo-propenyl;

R 4 is hydrogen, fluoro, (2E)-3-N-hydroxyamino-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

R 5 is hydrogen, chloro, fluoro, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl; and

R 6 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof;

(B) or wherein:

R 1 , R 2 , R 5 and R 6 are each as defined in (A) above;

R 3 is hydrogen or (2E)-3-N-hydroxyamino-3-oxo-propenyl; and

R 4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

(C) or wherein:

R 1 , R 2 , R 4 and R 6 are each as defined in (A) above;

R 3 is as defined in (B) above; and

R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl;

(D) or wherein:

R 1 , R 2 , R 4 and R 5 are each as defined in (A) above;

R 3 is as defined in (B) above; and

R 6 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof.

3. The method of claim 2 ,

(i) wherein:

R 1 is hydrogen, methyl, ethyl, cyclopropyl, or isopropyl;

R 2 is phenyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-(1H-indol-3-yl)ethyl, 2-(4-fluorophenyl)ethyl, or 2-(4-methoxyphenyl)ethyl;

R 3 is (2E)-3-N-hydroxyamino-3-oxo-propenyl;

R 4 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

R 5 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl; and

R 6 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof;

(ii) or wherein:

R 1 , R 2 , R 5 and R 6 are each as defined in (i) above;

R 3 is hydrogen or (2E)-3-N-hydroxyamino-3-oxo-propenyl; and

R 4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

(iii) or wherein:

R 1 , R 2 , R 4 and R 6 are each as defined in (i) above;

R 3 is as defined in (ii) above; and

R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl;

(iv) or wherein:

R 1 , R 2 , R 4 and R 5 are each as defined in (i) above;

R 3 is as defined in (ii) above; and

R 6 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof.

4. The method of claim 2 , wherein

R 1 is ethyl;

R 2 is 2-phenylethyl;

R 3 is hydrogen;

R 4 is fluoro;

R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and

R 6 is hydrogen, or a salt thereof.

5. The method of claim 2 , wherein

R 1 is ethyl;

R 2 is 2-phenylethyl;

R 3 is hydrogen;

R 4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl;

R 5 is chloro or fluoro; and

R 6 is hydrogen, or a salt thereof.

6. The method of claim 2 , wherein the compound is selected from the group consisting of

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-5-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-6-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-8-yl)-N-hydroxyacrylamide,

(2E)-3-(3-benzyl-3,4-dihydro-2-methyl-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3-(2-(1H-indol-3-yl)ethyl)-3,4-dihydro-2-methyl-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(2-ethyl-3,4-dihydro-4-oxo-3-(3-phenylpropyl)quinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(2-cyclopropyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-isopropyl-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3-(4-methoxyphenethyl)-2-ethyl-3,4-dihydro-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3-(4-fluorophenethyl)-2-ethyl-3,4-dihydro-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

4-((2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)methyl)-N-hydroxybenzamide,

4-((2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)methyl)-N-hydroxy benzamide,

4-((2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-8-yl)methyl)-N-hydroxy benzamide,

4-(2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-8-yl)-N-hydroxybenzamide, and

(2E)-N-(2-aminophenyl)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenethylquinazolin-7-yl)acrylamide.

7. The method of claim 2 , wherein the compound is (2E)-3-(2-ethyl-6-fluoro-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide, or a salt thereof.

8. The method of claim 2 , wherein the compound is (2E)-3-(2-ethyl-7-fluoro-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)-N-hydroxyacrylamide, (2E)-3-(7-chloro-2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)-N-hydroxyacrylamide, or a salt thereof.

9. The method of claim 1 , wherein the cancer is at least one selected from the group consisting of pancreatic carcinoma, hepatocellular carcinoma, colon tumor, breast tumor, prostate tumor, lymphoma and cutaneous tumor.

10. The method of claim 9 , wherein the cutaneous tumor is at least one selected from the group consisting of melanomas and basal carcinomas.

11. The method of claim 1 , wherein the cancer is at least one selected from the group consisting of breast cancer, colon cancer, large cell lung cancer, adenocarcinoma of the lung, small cell lung cancer, stomach cancer, liver cancer, ovary adenocarcinoma, pancreas carcinoma, prostate carcinoma, promylocytic leukemia, chronic myelocytic leukemia, and acute lymphocytic leukemia.

12. A method for inhibiting growth of cancer cells in a patient having a cancer associated with deregulation of the activity of histone deacetylases, comprising:

administering to the patient a compound of Formula X:

or a pharmaceutically acceptable salt thereof in a therapeutically effective amount to inhibit the growth of the cancer cells in the patient having a cancer associated with deregulation of the activity of histone deacetylases,

(I) wherein:

R 1 is hydrogen, (C 1 -C 6 )alkyl, or (C 3 -C 6 )cycloalkyl;

R 2 is (C 6 -C 18 )aryl, (C 6 -C 18 )aryl(C 1 -C 6 )alkyl, (C 3 -C 18 )heteroaryl(C 1 -C 6 )alkyl, halo(C 6 -C 18 )aryl(C 1 -C 6 )alkyl, or (C 1 -C 6 )alkoxy(C 6 -C 18 )aryl(C 1 -C 6 )alkyl;

R 3 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl;

R 4 is hydrogen, halogen, N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene;

R 5 is hydrogen, halogen, N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene, or amino(C 6 -C 18 )aryl-oxo(C 2 -C 6 )alkenyl; and

R 6 is hydrogen, N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyamino(C 6 -C 18 )aryl (C 1 -C 6 )alkylene, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene;

(II) or wherein:

R 1 , R 2 , R 5 and R 6 are each as defined in (I) above;

R 3 is hydrogen or N-hydroxyamino-oxo(C 2 -C 6 )alkenyl; and

R 4 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene;

(III) or wherein:

R 1 , R 2 , R 4 and R 6 are each as defined in (I) above;

R 3 is as defined in (II) above; and

R 5 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene, or amino(C 6 -C 18 )aryl-oxo(C 2 -C 6 )alkenyl;

(IV) or wherein:

R 1 , R 2 , R 4 , R 5 are each as defined in (I) above;

R 3 is as defined in (II) above; and

R 6 is N-hydroxyamino-oxo(C 2 -C 6 )alkenyl, N-hydroxyamino(C 6 -C 18 )aryl (C 1 -C 6 )alkylene, or N-hydroxyaminocarbonyl(C 6 -C 18 )aryl(C 1 -C 6 )alkylene.

13. The method of claim 12 ,

(A) wherein:

R 1 is hydrogen, methyl, ethyl, cyclopropyl, or isopropyl;

R 2 is phenyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-(1H-indol-3-yl)ethyl, 2-(4-fluorophenyl)ethyl, or 2-(4-methoxyphenyl)ethyl;

R 3 is (2E)-3-N-hydroxyamino-3-oxo-propenyl;

R 4 is hydrogen, fluoro, (2E)-3-N-hydroxyamino-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

R 5 is hydrogen, chloro, fluoro, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl; and

R 6 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof;

(B) or wherein:

R 1 , R 2 , R 5 and R 6 are each as defined in (A) above;

R 3 is hydrogen or (2E)-3-N-hydroxyamino-3-oxo-propenyl; and

R 4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

(C) or wherein:

R 1 , R 2 , R 4 and R 6 are each as defined in (A) above;

R 3 is as defined in (B) above; and

R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl;

(D) or wherein:

R 1 , R 2 , R 4 and R 5 are each as defined in (A) above;

R 3 is as defined in (B) above; and

R 6 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof.

14. The method of claim 13 ,

(i) wherein:

R 1 is hydrogen, methyl, ethyl, cyclopropyl, or isopropyl;

R 2 is phenyl, benzyl, 2-phenylethyl, 3-phenylpropyl, 2-(1H-indol-3-yl)ethyl, 2-(4-fluorophenyl)ethyl, or 2-(4-methoxyphenyl)ethyl;

R 3 is (2E)-3-N-hydroxyamino-3-oxo-propenyl;

R 4 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

R 5 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl; and

R 6 is hydrogen, (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof;

(ii) or wherein;

R 1 , R 2 , R 5 and R 6 are each as defined in (i) above;

R 3 is hydrogen or (2E)-3-N-hydroxyamino-3-oxo-propenyl; and

R 4 is (2E)-3-N-hydroxyamino-3-oxo-3-oxo-propenyl, or 4-(N-hydroxyaminocarbonyl)benzyl;

(iii) or wherein:

R 1 , R 2 , R 5 and R 6 are each as defined in (i) above;

R 3 is as defined in (ii) above; and

R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)benzyl, or (2E)-3-N-(2-aminophenyl)-3-oxo-propenyl;

(iv) or wherein:

R 1 , R 2 , R 4 and R 5 are each as defined in (i) above;

R 3 is as defined in (ii) above; and

R 6 is (2E)-3-N-hydroxyamino-3-oxo-propenyl, 4-(N-hydroxyaminocarbonyl)phenyl, or 4-(N-hydroxyaminocarbonyl)benzyl, or a salt thereof.

15. The method of claim 13 , wherein

R 1 is ethyl;

R 2 is 2-phenylethyl;

R 3 is hydrogen;

R 4 is fluoro;

R 5 is (2E)-3-N-hydroxyamino-3-oxo-propenyl; and

R 6 is hydrogen, or a salt thereof.

16. The method of claim 13 , wherein

R 1 is ethyl;

R 2 is 2-phenylethyl;

R 3 is hydrogen;

R 4 is (2E)-3-N-hydroxyamino-3-oxo-propenyl;

R 5 is chloro or fluoro; and

R 6 is hydrogen, or a salt thereof.

17. The method of claim 13 , wherein the compound is selected from the group consisting of

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-5-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-6-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenylquinazolin-8-yl)-N-hydroxyacrylamide,

(2E)-3-(3-benzyl-3,4-dihydro-2-methyl-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3-(2-(1H-indol-3-yl)ethyl)-3,4-dihydro-2-methyl-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(2-ethyl-3,4-dihydro-4-oxo-3-(3-phenylpropyl)quinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(2-cyclopropyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3,4-dihydro-2-isopropyl-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3-(4-methoxyphenethyl)-2-ethyl-3,4-dihydro-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

(2E)-3-(3-(4-fluorophenethyl)-2-ethyl-3,4-dihydro-4-oxoquinazolin-7-yl)-N-hydroxyacrylamide,

4-((2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)methyl)-N-hydroxybenzamide,

4-((2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)methyl)-N-hydroxybenzamide,

4-((2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-8-yl)methyl)-N-hydroxybenzamide,

4-(2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-8-yl)-N-hydroxybenzamide and

(2E)-N-(2-aminophenyl)-3-(3,4-dihydro-2-methyl-4-oxo-3-phenethylquinazolin-7-yl)acrylamide.

18. The method of claim 13 , wherein the compound is (2E)-3-(2-ethyl-6-fluoro-3,4-dihydro-4-oxo-3-phenethylquinazolin-7-yl)-N-hydroxyacrylamide, or a salt thereof.

19. The method of claim 13 , wherein the compound is (2E)-3-(2-ethyl-7-fluoro-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)-N-hydroxyacrylamide, (2E)-3-(7-chloro-2-ethyl-3,4-dihydro-4-oxo-3-phenethylquinazolin-6-yl)-N-hydroxyacrylamide, or a salt thereof.

20. The method of claim 13 , wherein the cancer is selected from the group consisting of lung adenocarcinoma, colorectal cancer, pancreatic carcinoma, and hepatocellular carcinoma.

Continuity (3)
Continuation 13855525 · Apr 2, 2013
Provisional Application 61622127 · Apr 10, 2012
Related Publication 20150196563A1 · Jul 16, 2015